Skip to content
Screener

Rigel Pharmaceuticals RIGL Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$69.5MBeat by $1.0M
EPS$1.46Beat by $0.53
Revenue estimate$68.4M
EPS estimate$0.93

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$80.1M
EPS estimate$0.92

Financials

Q3 2025

Income statement

See full
Revenue$69.5M+25.6%
Gross profit$64.7M+36.9%
Operating income$28.4M+102%
Net income$27.9M+125%
EPS (diluted)$1.46+109%

Balance sheet

See full
Cash & equivalents$48.5M-6.1%
Total debt$1.2M+147%
Total equity$117.6M+904%
Total assets$242.5M+74.0%

Cash flow

See full
Operating cash flow$24.0M+10.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$508.16M+78.5%
Enterprise value$460.78M+97.4%
P/E4.5×-86.1×
P/S1.8×0.0×

Profitability

See full
Gross margin93.1%+3.7pp
Operating margin42.2%+37.4pp
Net margin40.2%+38.2pp

Returns & leverage

See full
Debt / equity0×—
Current ratio2.3×+0.3×

Segments

By product

See full
Gross product sales$85.6M+52.0%
Delivery of drug supplies, royalties and others$5.4M-15.4%
Discounts and allowances-$21.6M-23.9%

FAQ

When did Rigel Pharmaceuticals report Q3 2025 earnings?
Rigel Pharmaceuticals (RIGL) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Rigel Pharmaceuticals's Q3 2025 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $69.5M and eps of $1.46 for Q3 2025.
Did Rigel Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $68.4M by $1.0M. EPS beat the consensus estimate of $0.93 by $0.53.
How did Rigel Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 25.6% from $55.3M a year earlier and eps grew 108.6% from $0.70.
Where can I find Rigel Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-106282) and the 10-Q periodic report (0001104659-25-106268) directly on SEC EDGAR. The filing index links above go to sec.gov.